MedTrace Logo

Simvastatin to Prevent SCI-Induced Bone Loss

NCT02946424 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2021-12-08

No results posted yet for this study

Summary

This is a double blind, randomized, placebo -controlled clinical trial with the primary goal of determining the osteogenic benefits of simvastatin in acute SCI.

Conditions

Interventions

DRUG

Placebo Oral Capsule

12 month course of daily placebo

DRUG

Simvastatin

12 month course of daily simvastatin

Sponsors & Collaborators

  • Craig Hospital

    lead OTHER

Principal Investigators

  • Leslie Morse, DO · Craig Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2023-09-30
Completion
2023-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02946424 on ClinicalTrials.gov